Viking begins VENTURE trial of dual glp-1/gip receptor agonist VK2735 for obesity
Viking Therapeutics has initiated a Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like...
Viking begins VENTURE trial of dual glp-1/gip receptor agonist VK2735 for obesity
Therapeutic polymer could provide alternative to gastric bypass
Survodutide GLP-1 receptor dual agonist to be assessed in three global Phase III studies for obesity
Researchers identify age-specific and sex-specific obesity genes
RELMalpha protein protects females against obesity
Obesogens generate misinformation and drive obesity
Individualised obesity therapy - tailoring interventions to a person's phenotypes